ID: ALA3407928

Max Phase: Preclinical

Molecular Formula: C17H17ClN2O3

Molecular Weight: 332.79

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(O)c1cc(-c2ccc(OC3CCCCC3)c(Cl)c2)ncn1

Standard InChI:  InChI=1S/C17H17ClN2O3/c18-13-8-11(14-9-15(17(21)22)20-10-19-14)6-7-16(13)23-12-4-2-1-3-5-12/h6-10,12H,1-5H2,(H,21,22)

Standard InChI Key:  CGERSASIIWHGRE-UHFFFAOYSA-N

Associated Targets(Human)

Kynurenine 3-monooxygenase 379 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver microsome 8277 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

MDCK 10148 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver microsome 4459 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver 8163 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 332.79Molecular Weight (Monoisotopic): 332.0928AlogP: 4.21#Rotatable Bonds: 4
Polar Surface Area: 72.31Molecular Species: ACIDHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 0.76CX Basic pKa: 5.29CX LogP: 2.71CX LogD: 1.04
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.91Np Likeness Score: -0.61

References

1. Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, Brown CJ, Cardaun I, Courtney SM, Dijkman U, Hamelin-Flegg E, Johnson PD, Kempf V, Lyons K, Matthews K, Mitchell WL, O'Connell C, Pena P, Powell K, Rassoulpour A, Reed L, Reindl W, Selvaratnam S, Friley WW, Weddell DA, Went NE, Wheelan P, Winkler C, Winkler D, Wityak J, Yarnold CJ, Yates D, Munoz-Sanjuan I, Dominguez C..  (2015)  Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.,  58  (3): [PMID:25590515] [10.1021/jm501350y]

Source